AmideBio discovers and develops peptide therapeutics for metabolic diseases. The company uses advanced in-silico techniques to intelligently design novel peptides, its proprietary BioPure™ process to efficiently synthesize them and testing to assess their biological activity. We are currently developing drug candidates in congenital hyperinsulinism - an ultra orphan indication where there is no satisfactory therapy, and glucose responsive insulin - a safer insulin that avoids the risks of impaired awareness of hypoglycemia, a dangerous condition for patients with diabetes.
AmideBio was founded in 2009 to commercialize BioPure platform technology to deliver difficult-to-manufacture, ultrapure peptides to the biopharmaceutical industry and research community. The company continues to sell these peptides to customers directly as well as offers a custom synthesis service. In 2016, the company began to leverage this capability to develop its own therapeutics targeting metabolic diseases.
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.amidebio.com/
Amidebio Llc Questions
Amidebio Llc's website is https://www.amidebio.com/
Amidebio Llc's LinkedIn profile is https://www.linkedin.com/company/amidebio-llc
Amidebio Llc has
2 employees.
View email and phone details for 2
employees at Amidebio Llc.
Amidebio Llc's industry is
Biotechnology Research
Amidebio Llc's top competitors are
Aigene,
Vona Oncology,
Topogen, Inc.,
Biomimetix,
Oncoverity, Inc,
Orbit Genomics,
Gracon Manufacturing Llc,
Corgenix Medical Corporation,
Kelsie Biotech Llc,
Photonpharma.
Amidebio Llc's categories are Biotechnology Research
Amidebio Llc's founding year is 2009
